{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-24-000024","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.239633+00:00","generated_at":"2026-06-02T18:37:03.945894+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inspire Medical Q1 revenue $164M (+28% YoY); raises FY2024 guidance, expects full-year profitability","bullets":["Q1 2024 revenue $164.0M, up 28% YoY; net loss narrowed to $10.0M ($0.34/share) from $15.4M.","U.S. revenue $155.8M (+25% YoY); OUS revenue $8.2M (+141%); gross margin 84.9% vs 84.4%.","FY2024 revenue guidance raised to $783-793M (25-27% growth); first-time diluted EPS guidance $0.10-$0.20.","Added 66 new U.S. centers (total 1,246) and 11 new sales territories (total 298) in Q1.","Ended Q1 with $469.2M cash; expects full-year 2024 profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-24-000024","json":"https://secwatch.observer/filing/0001609550-24-000024.json","markdown":"https://secwatch.observer/filing/0001609550-24-000024.md","text":"https://secwatch.observer/filing/0001609550-24-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000024/0001609550-24-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000024/insp-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:37:03.945894+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5d9f8453846fc31b7ad7733e902954eff94eb35","claim":"Inspire Medical Systems, Inc. reported the full year 2024 results: revenue $783 million to $793 million. Guidance raised.","evidence_excerpt":"Inspire is initiating first-time diluted net income per share guidance for the full year 2024 of between $0.10 to $0.20 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000024/0001609550-24-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2024"},{"label":"Revenue","value":"$783 million to $793 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}]},{"claim_id":"c5d9f8453846fc31b7ad7733e902954eff94eb35","claim":"Inspire Medical Systems, Inc. reported the full year 2024 results: revenue $783 million to $793 million. Guidance raised.","evidence_excerpt":"Inspire is increasing its full year 2024 revenue guidance to between $783 million to $793 million, which represents growth of 25% to 27% over full year 2023 revenue of $624.8 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000024/0001609550-24-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2024"},{"label":"Revenue","value":"$783 million to $793 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}]},{"claim_id":"c5ee4c2f974ba1eee4727c58f06b4792b9fda1f5","claim":"Inspire Medical Systems, Inc. reported the quarter ended March 31, 2024 results: revenue $164.0 million, net income $10.0 million net loss, EPS $0.34 per share net loss per share.","evidence_excerpt":"Revenue was $164.0 million for the three months ended March 31, 2024, a 28% increase from $127.9 million in the corresponding period in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955024000024/0001609550-24-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$164.0 million"},{"label":"Net income","value":"$10.0 million net loss"},{"label":"EPS","value":"$0.34 per share net loss per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}